CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
I'm PortAI, I can summarize articles.
Kahn Swick & Foti, LLC is investigating the proposed sale of Dynavax Technologies Corporation (DVAX) to Sanofi, where shareholders would receive $15.50 per share. The firm aims to assess the adequacy of this price and the process leading to the sale, questioning if it undervalues the company. Interested parties can contact KSF for more information regarding their legal rights in this matter.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments